Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction

Inclusion Criteria: * Age ≥ 18 years * New York Heart Association(NYHA) functional classification II - IV * LVEF measured by the echocardiogram ≤ 45% * eGFR\>25mL/min/1.73m² Exclusion Criteria: * LVEF measured by the echocardiogram \> 45% * History of allergic or hypersensitivity to drugs involved in the trial. * Patients with a known history of cancer, angioedema, significant congenital heart disease or rheumatic heart disease. * Patients diagnosed with myocarditis. * Probable alternative diagnoses could account for the patient's HF symptoms e.g., COPD, bronchial asthma, primary pulmonary hypertension. * Systolic blood pressure (SBP) ≥180mmHg or diastolic blood pressure (DBP) * 120mmHg at visit, DBP≤90mmHg or symptomatic hypotension. * Patients with cardiac pacemaker * Pregnant woman * eGFR≤25mL/min/1.73m² and not accept long-term hemodialysis therapy. * Serum potassium \>5.2 mmol/l at visit * Fatal or uncontrollable heart arrythmia e.g., symptomatic or persistence ventricular tachycardia, ventricular rate\>150 bpm in AF patients. * Obvious stenosis (≥50%) of bilateral renal arteries.